LexaGene to Place MiQLab Systems at Two Leading Specialty and Emergency Veterinary Care Hospitals
December 17 2020 - 7:58AM
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the
“
Company”), a molecular diagnostics company that
develops fully automated rapid pathogen detection systems, is
pleased to announce that it will place MiQLab™ systems into the
busy clinical practices of two specialty and emergency veterinary
hospitals as part of LexaGene’s Early Access Program.
LexaGene will provide access to its point-of-care technology to
both Veterinary Specialty Hospital (VSH) of Palm Beach Gardens,
Florida, as well as to Denver Animal Emergency (Denver) in Denver,
North Carolina. Both practices will evaluate the MiQLab system and
MiQLab Bacterial AMR Test in specialty and critical care settings
using a range of sample types.
Dr. Jack Regan, LexaGene’s CEO and Founder states, “We are very
excited to be placing MiQLab systems at innovative veterinary
hospitals like VSH and Denver. We expect these systems to
demonstrate the advantage of having in-house automated rapid
testing for pathogens and antibiotic resistance markers, which is
expected to improve patient care and clinical outcomes. The
feedback we receive from these industry leading practices will help
us in our efforts to gain wide adoption in this market.”
MiQLab-generated data will be evaluated against traditional
culture and sensitivity testing that typically takes 3-5 days for
results. By contrast, MiQLab provides results fast enough to allow
care providers to make knowledge-based decisions for timely patient
care. This is particularly important for appropriately treating
animals infected with multi-drug resistant pathogens.
Dr. Jorg Bucheler, DVM, PhD, DACVIM (SAIM), ECVIM and practice
owner of VSH states, “I am very pleased that VSH will be able to
evaluate LexaGene’s MiQLab system. We pride ourselves on using the
very latest technology and techniques in specialty and critical
care to deliver the highest level of service we can provide our
patients. Having access to rapid PCR in-clinic testing will allow
us to triage critical and complicated infections more
effectively.”
Dr. Andrew Pierce, DVM, Owner and Medical Director of Denver
adds, “We are looking forward to gaining access to LexaGene’s
MiQLab system for testing in our emergency care practice. To have
this type of technology available where rapid time-to-answer really
matters is ground-breaking for our line of work.”
LexaGene expects to place systems for these evaluations shortly
after the new year.
To be added to the LexaGene email list, please subscribe on the
Company website.
On Behalf of the Board of DirectorsDr.
Jack ReganChief Executive Officer &
Director
About LexaGene Holdings Inc.LexaGene is a
molecular diagnostics company that develops molecular diagnostic
systems for pathogen detection and genetic testing for other
molecular markers for on-site rapid testing in veterinary
diagnostics, food safety and for use in open-access markets such as
clinical research, agricultural testing and biodefense. End-users
simply need to collect a sample, load it onto the instrument with a
sample preparation cartridge, enter sample ID and press ‘go’. The
MiQLab™ system delivers excellent sensitivity, specificity, and
breadth of detection and can return results in approximately one
hour. The unique open-access feature is designed for custom testing
so that end-users can load their own real-time PCR assays onto the
instrument to target any genetic target of interest.
About VSHVeterinary Specialty
Hospital of Palm Beach Gardens in Florida provides specialty and
critical/emergency 24-hour care to thousands of patients each year,
treating complex veterinary cases in areas such as surgery,
oncology, dermatology, neurology, cardiology, and internal
medicine.
About DenverDenver Animal
Emergency, located in North Carolina, provides 24/7 emergency care
to support pet owners and local veterinary practices during
critical times.
For further information, please contact:
Media ContactsNicole RidgedaleDirector of
Corporate Marketing, LexaGene800.215.1824 ext
206nridgedale@lexagene.com
Investor RelationsJay AdelaarVice President of
Capital Markets, LexaGene800.215.1824 ext
207jadelaar@lexagene.com
The TSX Venture Exchange Inc. has in no way
passed upon the merits of the proposed transaction and has neither
approved nor disapproved the contents of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This news release contains forward-looking information, which
involves known and unknown risks, uncertainties and other factors
that may cause actual events to differ materially from current
expectation. Important factors -- including the availability of
funds, the results of financing efforts, the success of technology
development efforts, the cost to procure critical parts,
performance of the instrument, market acceptance of the technology,
regulatory acceptance, and licensing issues -- that could cause
actual results to differ materially from the Company's expectations
as disclosed in the Company's documents filed from time to time on
SEDAR (see www.sedar.com). Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. The company disclaims
any intention or obligation, except to the extent required by law,
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jul 2023 to Jul 2024